Statement Of Cash Flows [Abstract]

Egetis Therapeutics - Filing #701621

Concept	As at 2021-12-31	2021-01-01 to 2021-12-31	As at 2020-12-31	2020-01-01 to 2020-12-31	As at 2019-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Profit (loss)	—	104 542 SEK	—	178 024 SEK	—
Adjustments to reconcile profit (loss) [abstract]
Other adjustments for non-cash items	—	2 683 SEK	—	1 334 SEK	—
Adjustments to reconcile profit (loss)	—	28 251 SEK	—	42 052 SEK	—
Income taxes paid (refund), classified as operating activities	—	– SEK	—	– SEK	—
Cash flows from (used in) operating activities	—	130 110 SEK	—	134 639 SEK	—
Cash flows from (used in) investing activities [abstract]
Cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities	—	5 000 SEK	—	59 520 SEK	—
Purchase of property, plant and equipment, classified as investing activities	—	172,000 SEK	—	24,000 SEK	—
Cash flows from (used in) investing activities	—	5 957 SEK	—	59 543 SEK	—
Cash flows from (used in) financing activities [abstract]
Proceeds from issuing shares	—	– SEK	—	250 750 SEK	—
Repayments of borrowings, classified as financing activities	—	7 500 SEK	—	– SEK	—
Payments of lease liabilities, classified as financing activities	—	1 402 SEK	—	215,000 SEK	—
Cash flows from (used in) financing activities	—	8 902 SEK	—	228 405 SEK	—
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes	—	144 969 SEK	—	34 223 SEK	—
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents	—	1 084 SEK	—	1 473 SEK	—
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes	—	144 969 SEK	—	34 223 SEK	—
Cash and cash equivalents	143 965 SEK	—	287 850 SEK	—	255 101 SEK